Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Aprea Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 18 | 19 | +1 |
| Shares | 848.4K | 881.8K | +33.4K (+3.9%) |
| Value | $3.77M | $2.78M | −$992.5K (−26.3%) |
New holders (3)
Institutions that held Aprea Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 23,590 | $74.3K | 0.00% |
| MB, Levis & Associates, LLC | 806 | $2.54K | 0.00% |
| Northwestern Mutual Wealth Management Co | 47 | $148 | 0.00% |
Sold out (2)
Institutions that held Aprea Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Bank of America Corp | 10 | $44 |
| Quent Capital, LLC | 3 | $13 |